Company intelligence / Profile preview
Ray Therapeutics
San Francisco, California, United Statesraytherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Ray Therapeutics is developing optogenetic gene therapies for vision restoration in patients with blinding diseases. Their lead product RTx-015 is in Phase 1 clinical trials for Retinitis Pigmentosa, aiming to restore visual acuity, contrast sensitivity, and visual field in patients with retinal blindness.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapyOptogenetics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Ray Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ray Therapeutics.